Business
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Reported Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference call scheduled for 4:30 p.m. ET today\nReported Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH, Showing up to 55% Median Liver Fat Reduction; 52 Week Biopsy Results Expected 1H24Phase 2 Study of Dual GLP-1/GIP Agonist VK2735 in Obesity Planned for 3Q23Phase 1 Trial of Oral VK2735 Ongoing; Results Expected 4Q23Strong Quarter-End Cash Position of $393MSAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2023, and provided an update on its clinical pipeline and other corporate developments.\n\n \n \n \n \n \n \n\n \nHighlights from the Quarter Ended June 30, 2023, and Other Recent Events:\n\"In the second quarter of 2023 Viking continued to build on the momentum achieved in the first quarter, following the successful Phase 1 results of the dual incretin receptor agonist VK2735 for obesity,\" stated Brian Lian, Ph.D., chief executive officer of Viking. \"During the second quarter, we reported top-line data from our Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed NASH and fibrosis. The results demonstrated robust efficacy on the primary endpoint of reduction in liver fat at 12 weeks, and reaffirmed prior data showing VK2809's promising tolerability and safety profile. We remain on track to report the histology data from VOYAGE in the first half of 2024. With our lead obesity candidate, VK2735, we expect to initiate a Phase 2 trial later this quarter, and report results in the first half of 2024. In addition, the Phase 1 trial of our novel oral formulation of VK2735 continues to enroll, and we expect to report the initial results from this study later this year. We ended the second quarter with approximately $393 million, placing us in a strong financial position, with runway to execute through multiple potential value-creating events.\"\nPipeline and Recent Corporate Highlights\nReported Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH. VK2809 is an orally available, small molecule agonist of the thyroid hormone receptor that is selective for...